Mylan Probe Clouds King Deal

Mylan Laboratories' rocky road toward acquiring King Pharmaceuticals has taken two more turns that could complicate a deal already mired in controversy. The Canonsburg generics drugmaker disclosed it was being investigated by the U.S. Justice Department over Medicaid drug rebates, an issue that has brought dozens of other drugmakers under regulatory scrutiny. Among them is Bristol, Tenn.-based King, which Mylan agreed to acquire in July for $4 billion.

Post-Gazette (http://www.post-gazette.com/pg/05042/455940.stm)